Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Accumulated Expenses (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Accumulated Expenses readings, the most recent being $1.9 million for Q4 2024.

  • On a quarterly basis, Accumulated Expenses changed 0.37% to $1.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.9 million, a 0.37% change, with the full-year FY2024 number at $1.9 million, changed 0.37% from a year prior.
  • Accumulated Expenses hit $1.9 million in Q4 2024 for Unicycive Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.1 million in Q2 2024 to a low of $1.2 million in Q4 2021.
  • Median Accumulated Expenses over the past 4 years was $1.9 million (2024), compared with a mean of $2.0 million.
  • The widest YoY moves for Accumulated Expenses: up 84.84% in 2024, down 44.58% in 2024.
  • Unicycive Therapeutics' Accumulated Expenses stood at $1.2 million in 2021, then grew by 22.69% to $1.5 million in 2022, then grew by 28.92% to $1.9 million in 2023, then fell by 0.37% to $1.9 million in 2024.
  • The last three reported values for Accumulated Expenses were $1.9 million (Q4 2024), $1.4 million (Q3 2024), and $3.1 million (Q2 2024) per Business Quant data.